All articles tagged with #vaccine technology
The FDA has approved Moderna’s mFlusiva as the United States' first mRNA flu vaccine, giving adults 50+ access with full approval for ages 50–64 and accelerated approval for 65+, following a trial that showed it outperformed a standard-dose flu vaccine and suggesting mRNA could speed vaccine updates to evolving flu strains and potentially improve seasonal vaccines.
A leading epidemiologist warns that current US pandemic response capacity has been severely diminished, and emphasizes the need for better preparedness, rapid vaccine development, and effective communication to mitigate the impact of future pandemics, which could be even more deadly than COVID-19.
The article critiques misconceptions about mRNA COVID-19 vaccines, emphasizing their safety, effectiveness, and rapid adaptability compared to traditional vaccines. It highlights recent political and funding shifts away from mRNA research, despite scientific evidence supporting their benefits, and discusses the potential of mRNA technology for future disease prevention. The author warns that misinformation and policy decisions based on false claims could hinder advancements and public health outcomes.
The Trump administration is reducing funding for mRNA vaccine development, which played a crucial role in COVID-19 response, citing a focus on safer, broader vaccine platforms. Experts warn this move could hinder future pandemic preparedness and the development of new vaccines for various diseases, despite the proven safety and effectiveness of mRNA technology in saving lives during the pandemic.
US Health Secretary RFK Jr has canceled $500 million in funding for mRNA vaccine research, citing concerns about their effectiveness against respiratory infections. Experts argue that while mRNA vaccines are not perfect, they have proven highly effective during the pandemic and are crucial for rapid response to outbreaks. The decision raises concerns about potential setbacks in vaccine development and broader implications for public health and future medical technologies.
The development of self-amplifying RNA (saRNA) vaccines represents a significant advancement in immunization, offering the potential for enhanced efficacy and reduced side effects. These next-generation vaccines build on the success of mRNA vaccines and have the ability to replicate within the body, potentially leading to a more robust immune response with smaller doses. While Japan recently approved an saRNA vaccine, concerns over safety, ethical implications, and the balance between innovation and regulation have sparked a debate within the scientific community and among regulators and the public.